{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:01:29Z","timestamp":1791475289689,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["LSHM-CT-2003-502941"],"award-info":[{"award-number":["LSHM-CT-2003-502941"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["4518"],"award-info":[{"award-number":["4518"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["12713"],"award-info":[{"award-number":["12713"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG11950"],"award-info":[{"award-number":["IG11950"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.canlet.2014.12.032","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T23:50:42Z","timestamp":1419033042000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The \u03b12\u03b21 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study"],"prefix":"10.1016","volume":"358","author":[{"given":"Nadia","family":"Rucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Capulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole K.","family":"Olstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"\u00d6nnerfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-9477","authenticated-orcid":false,"given":"Viveka","family":"Tillgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaare M.","family":"Gautvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Heineg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Teti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.12.032_bib0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2014.12.032_bib0015","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2014.12.032_bib0020","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.canlet.2014.12.032_bib0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","article-title":"Bone metastasis: pathogenesis and therapeutic implications","volume":"24","author":"Clezardin","year":"2007","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2014.12.032_bib0030","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/jbmr.2206","article-title":"The c-terminl domain of chondroadherin: a new regulator of osteoclast motility counteracting bone loss","volume":"29","author":"Capulli","year":"2014","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.canlet.2014.12.032_bib0035","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","article-title":"Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with bisphophonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2","volume":"99","author":"Yoneda","year":"1997","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2014.12.032_bib0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy","volume":"318","author":"Rucci","year":"2006","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"10.1016\/j.canlet.2014.12.032_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1145\/37402.37422","article-title":"Marching cubes: a high resolution 3d surface construction algorithm","volume":"21","author":"Lorensen","year":"1987","journal-title":"Comput. Graph. (ACM)"},{"key":"10.1016\/j.canlet.2014.12.032_bib0050","series-title":"Digital Image Processing","author":"Pratt","year":"1991"},{"key":"10.1016\/j.canlet.2014.12.032_bib0055","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.canlet.2014.12.032_bib0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res"},{"key":"10.1016\/j.canlet.2014.12.032_bib0065","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2174\/138161211796904812","article-title":"Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol","volume":"17","author":"Pereira","year":"2011","journal-title":"Curr. Pharm. Des"},{"key":"10.1016\/j.canlet.2014.12.032_bib0070","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.12.032_bib0075","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2014.12.032_bib0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/bcr2818","article-title":"Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management","volume":"13","author":"Gaillard","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2014.12.032_bib0085","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","article-title":"Risks and benefits of bisphosphonates","volume":"98","author":"Coleman","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2014.12.032_bib0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2007","journal-title":"Nat. Clin. Pract. Oncol"},{"key":"10.1016\/j.canlet.2014.12.032_bib0095","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.12.032_bib0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"Am. J. Clin. Oncol"},{"key":"10.1016\/j.canlet.2014.12.032_bib0105","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2014.12.032_bib0110","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2013.05.015","article-title":"Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-\u03baB ligand inhibitors in patients with advanced prostate cancer","volume":"65","author":"Gartrell","year":"2014","journal-title":"Eur. Urol"},{"key":"10.1016\/j.canlet.2014.12.032_bib0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat. Rev"},{"key":"10.1016\/j.canlet.2014.12.032_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11010-010-0657-5","article-title":"Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells","volume":"349","author":"Bokobza","year":"2011","journal-title":"Mol. Cell. Biochem"},{"key":"10.1016\/j.canlet.2014.12.032_bib0125","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cell.2006.09.044","article-title":"Forced sensing by mechanical extension of the Src family kinase substrate p130Cas","volume":"127","author":"Sawada","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.12.032_bib0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/jnci\/92.2.120","article-title":"Bcar1\/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment","volume":"92","author":"van der Flier","year":"2000","journal-title":"J. Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2014.12.032_bib0135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nrc3050","article-title":"The calpain system and cancer","volume":"11","author":"Storr","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.12.032_bib0140","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/annonc\/mds176","article-title":"Calpain system protein expression in basal-like and triple-negative invasive breast cancer","volume":"23","author":"Storr","year":"2012","journal-title":"Ann. Oncol"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514007873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514007873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T19:24:04Z","timestamp":1589484244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514007873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0304383514007873"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.12.032","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The \u03b12\u03b21 binding domain of chondroadherin inhibits breast cancer-induced bone metastases and impairs primary tumour growth: A preclinical study","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}